We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

BKM120+Abiraterone Acetate for Metastatic CRPC

This study has been terminated.
(Due to continued slow accrual the supllier of BKM120 requested that we cease further enrollment.)
ClinicalTrials.gov Identifier:
First Posted: December 5, 2012
Last Update Posted: January 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Glenn Bubley, MD, Dana-Farber Cancer Institute
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)